Povidone-iodine

Generic Name: Povidone-iodine

Brand Names: Betadine, Kenalog, Marbeta, Marcaine, P-Care M, P-Care MG, P-care, P-care X, Summer's Eve Medicated

Drug Type: Small Molecule

CAS Number: 25655-41-8

Unique Ingredient Identifier: 85H0HZU99M

Background: Povidone-iodine is a stable chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine. It contains from 9.0% to 12.0% available iodine, calculated on a dry basis. This unique complex was discovered in 1955 at the Industrial Toxicology Laboratories in Philadelphia by H. A. Shelanski and M. V. Shelanski. During in vitro testing to demonstrate anti-bacterial activity it was found that the complex was less toxic in mice than tincture of iodine. Human clinical trials showed the product to be superior to other iodine formulations. Povidone-iodine was immediately marketed, and has since become the universally preferred iodine antiseptic.

Indication: For topical application in the treatment and prevention of infection in wounds.

Associated Conditions: Skin Infections

Associated Therapies: Skin disinfection, Antiseptic skin preparation therapy, Irrigation of the ocular surface therapy, Prepping of the periocular region

Clinical Trials

Povidone-iodine vs Saline Solution in Colorectal Surgeries and Its Effects on the Surgical Site Infection

Phase 3

Recruiting

Conditions: Surgical Site Infection

Interventions: Drug: Saline solution
Drug: Povidone-iodine

First Posted Date: 2024-03-08

Last Posted Date: 2024-03-08

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 228

Registration Number: NCT06302335

Locations: 🇧🇷
Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil

Effectiveness of Povidone-Iodine Versus Chlorhexidine Gluconate Solutions in Reducing Microbial Contamination in Spinal Surgery Wounds During Intraoperative Soaking.

Not Applicable

Recruiting

Conditions: Spine Infection

Interventions: Drug: Povidone-iodine solution; chlorhexidine gluconate

First Posted Date: 2024-02-28

Last Posted Date: 2024-02-28

Lead Sponsor: National Cheng-Kung University Hospital

Target Recruit Count: 105

Registration Number: NCT06284174

Locations: 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan

Lidocaine, Povidone Iodine, and Honey Application on Second-degree Perineal Tear Healing

Phase 4

Completed

Conditions: Perineal Tear

Interventions: Other: control groups
Drug: honey
Drug: lidocaine
Drug: povidone-iodine

First Posted Date: 2023-07-14

Last Posted Date: 2023-07-14

Lead Sponsor: Hasanuddin University

Target Recruit Count: 200

Registration Number: NCT05946005

Locations: 🇮🇩
Wahidin Sudirohusodo Hospital, Makassar, South Sulawesi, Indonesia

SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep in Total Shoulder Arthroplasty

Phase 4

Completed

Conditions: Surgery
Surgical Site Infection
Cutibacterium Acnes
Prosthetic-joint Infection

Interventions: Device: SURGX Wound Gel
Drug: Povidone-Iodine

First Posted Date: 2023-06-26

Last Posted Date: 2024-12-10

Lead Sponsor: St. Louis University

Target Recruit Count: 60

Registration Number: NCT05919888

Locations: 🇺🇸
Saint Louis University, Saint Louis, Missouri, United States

Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis

Phase 1

Recruiting

Conditions: Knee Osteoarthritis

Interventions: Drug: Kenalog with bupivacaine Injection

First Posted Date: 2023-06-15

Last Posted Date: 2024-12-09

Lead Sponsor: Foundation for Orthopaedic Research and Education

Target Recruit Count: 75

Registration Number: NCT05906433

Locations: 🇺🇸
Florida Orthopaedic Institute, Tampa, Florida, United States

Oro-nasal Decontamination to Prevent Ventilator-associated Pneumonia

Phase 2

Completed

Conditions: Ventilator Associated Pneumonia

Interventions: Drug: Saline spray
Drug: Povidone-Iodine

First Posted Date: 2023-06-09

Last Posted Date: 2023-11-27

Lead Sponsor: Menoufia University

Target Recruit Count: 78

Registration Number: NCT05895773

Locations: 🇪🇬
Menoufia University hospitals, Shibīn Al Kawm, Menoufia, Egypt

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis

Phase 2

Completed

Conditions: Acute Bacterial Conjunctivitis

Interventions: Drug: IVIEW-1201
Drug: Ofloxacin Eye Drops

First Posted Date: 2023-04-18

Last Posted Date: 2023-10-18

Lead Sponsor: IVIEW Therapeutics Inc.

Target Recruit Count: 129

Registration Number: NCT05816070

Locations: 🇨🇳
Eye Hospital of Shandong First Medical University, Jinan, SHAN DONG, China

PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study)

Phase 4

Recruiting

Conditions: Surgical Site Infection

Interventions: Drug: povidone-iodine topical ointment

First Posted Date: 2023-03-10

Last Posted Date: 2024-05-16

Lead Sponsor: Loreen Herwaldt

Target Recruit Count: 2000

Registration Number: NCT05763602

Locations: 🇺🇸
University of Indiana, Indianapolis, Indiana, United States
🇺🇸
University of Utah, Salt Lake City, Utah, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States

and more 3 locations